{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:04:03Z","timestamp":1789603443587,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-58787-2","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:37:27Z","timestamp":1782304647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study"],"prefix":"10.1038","volume":"16","author":[{"given":"Dong Hyeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsock","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Hun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngoh","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyounggyoon","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom-Seok","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yil-Seob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonsuk","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"58787_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad, E., Lim, S., Lamptey, R., Webb, D. R. & Davies, M. J. Type 2 diabetes. Lancet 400, 1803\u20131820 (2022).","journal-title":"Lancet"},{"key":"58787_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto, E. et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and microvascular complications. Eur. J. Prev. Cardiol. 26, 25\u201332 (2019).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"58787_CR3","first-page":"e76498","volume":"16","author":"WN Hauwanga","year":"2024","unstructured":"Hauwanga, W. N. et al. The pathophysiology and vascular complications of diabetes in chronic kidney disease: A comprehensive review. Cureus 16, e76498 (2024).","journal-title":"Cureus"},{"key":"58787_CR4","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 45, 2753\u20132786 (2022).","journal-title":"Diabetes Care"},{"key":"58787_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/jdi.14363","volume":"16","author":"KH Ha","year":"2025","unstructured":"Ha, K. H., Shin, S., Na, E. & Kim, D. J. Trends in prescribing sodium-glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular-renal disease in South Korea, 2015\u20132021. J. Diabetes Investig. 16, 215\u2013224 (2025).","journal-title":"J. Diabetes Investig"},{"key":"58787_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N Engl. J. Med."},{"key":"58787_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPAKIDNEY The","year":"2023","unstructured":"The, E. M. P. A. K. I. D. N. E. Y. et al. Empagliflozin in patients with chronic kidney disease. N Engl. J. Med. 388, 117\u2013127 (2023).","journal-title":"N Engl. J. Med."},{"key":"58787_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl. J. Med. 380, 347\u2013357 (2019).","journal-title":"N Engl. J. Med."},{"key":"58787_CR9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl. J. Med. 373, 2117\u20132128 (2015).","journal-title":"N Engl. J. Med."},{"key":"58787_CR10","doi-asserted-by":"publisher","first-page":"e031805","DOI":"10.1161\/JAHA.123.031805","volume":"13","author":"R Kani","year":"2024","unstructured":"Kani, R. et al. Comparison of effectiveness among different sodium-glucose cotransporter-2 inhibitors according to underlying conditions: A network meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 13, e031805 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"58787_CR11","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10741-020-09954-8","volume":"26","author":"T T\u00e4ger","year":"2021","unstructured":"T\u00e4ger, T. et al. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors for cardiovascular outcomes in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Heart Fail. Rev. 26, 1421\u20131435 (2021).","journal-title":"Heart Fail. Rev."},{"key":"58787_CR12","doi-asserted-by":"publisher","first-page":"ehae666","DOI":"10.1093\/eurheartj\/ehae666.1060","volume":"45","author":"S Bu","year":"2024","unstructured":"Bu, S. et al. Comparative outcomes between empagliflozin and dapagliflozin in heart failure: Real-world multicenter cohort study. Eur. Heart J. 45, ehae666\u20131060 (2024).","journal-title":"Eur. Heart J."},{"key":"58787_CR13","doi-asserted-by":"publisher","first-page":"e24248","DOI":"10.1002\/clc.24248","volume":"47","author":"JH Kim","year":"2024","unstructured":"Kim, J. H. et al. Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus. Clin. Cardiol. 47, e24248 (2024).","journal-title":"Clin. Cardiol."},{"key":"58787_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(19)33177-0","volume":"395","author":"A Cipriani","year":"2020","unstructured":"Cipriani, A. et al. Generating comparative evidence on new drugs and devices after approval. Lancet 395, 998\u20131010 (2020).","journal-title":"Lancet"},{"key":"58787_CR15","doi-asserted-by":"publisher","first-page":"e077582","DOI":"10.1136\/bmjopen-2023-077582","volume":"14","author":"A Dugard","year":"2024","unstructured":"Dugard, A., Giraudeau, B. & Dibao-Dina, C. Do patients with type 2 diabetes mellitus included in randomized clinical trials differ from general-practice patients? A cross-sectional comparative study. BMJ Open. 14, e077582 (2024).","journal-title":"BMJ Open."},{"key":"58787_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell, P. M. External validity of randomized controlled trials: To whom do the results of this trial apply? Lancet 365, 82\u201393 (2005).","journal-title":"Lancet"},{"key":"58787_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/eurheartj\/ehac810","volume":"44","author":"L Filbey","year":"2023","unstructured":"Filbey, L. et al. Improving representativeness in trials: A call to action from the Global Cardiovascular Clinical Trialists Forum. Eur. Heart J. 44, 921\u2013930 (2023).","journal-title":"Eur. Heart J."},{"key":"58787_CR18","doi-asserted-by":"crossref","unstructured":"Rashidian, A., Omidvari, A. H., Vali, Y., Sturm, H. & Oxman, A. D. Pharmaceutical policies: Effects of financial incentives for prescribers. Cochrane Database Syst. Rev. 2015, CD006731 (2015).","DOI":"10.1002\/14651858.CD006731.pub2"},{"key":"58787_CR19","doi-asserted-by":"publisher","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","volume":"40","author":"LY Lin","year":"2018","unstructured":"Lin, L. Y., Warren-Gash, C., Smeeth, L. & Chen, P. C. Data resource profile: The National Health Insurance Research Database (NHIRD). Epidemiol. Health. 40, e2018062 (2018).","journal-title":"Epidemiol. Health"},{"key":"58787_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/endrev\/bnab007","volume":"42","author":"S Schneeweiss","year":"2021","unstructured":"Schneeweiss, S. & Patorno, E. Conducting real-world evidence studies on the clinical outcomes of diabetes treatments. Endocr. Rev. 42, 658\u2013690 (2021).","journal-title":"Endocr. Rev."},{"key":"58787_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.012","volume":"200","author":"SD Wiviott","year":"2018","unstructured":"Wiviott, S. D. et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE-TIMI 58) trial. Am. Heart J. 200, 83\u201389 (2018).","journal-title":"Am. Heart J."},{"key":"58787_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon, V. State-of-the-art review: Mechanisms of action of SGLT2 inhibitors and clinical implications. Am. J. Hypertens. 37, 841\u2013852 (2024).","journal-title":"Am. J. Hypertens."},{"key":"58787_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","volume":"53","author":"AJ Scheen","year":"2014","unstructured":"Scheen, A. J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium-glucose cotransporter 2 inhibitor. Clin. Pharmacokinet. 53, 213\u2013225 (2014).","journal-title":"Clin. Pharmacokinet."},{"key":"58787_CR24","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","volume":"20","author":"P Fioretto","year":"2018","unstructured":"Fioretto, P. et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment: The DERIVE study. Diabetes Obes. Metab. 20, 2532\u20132540 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"58787_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12933-023-01911-7","volume":"22","author":"J Lim","year":"2023","unstructured":"Lim, J. et al. Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: A nationwide population-based cohort study. Cardiovasc. Diabetol. 22, 188 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"58787_CR26","doi-asserted-by":"publisher","first-page":"e030552","DOI":"10.1161\/JAHA.123.030552","volume":"13","author":"J Lim","year":"2024","unstructured":"Lim, J. et al. Differing efficacy of dapagliflozin versus empagliflozin on the risk of incident atrial fibrillation in patients with type 2 diabetes: A nationwide population-based cohort study. J. Am. Heart Assoc. 13, e030552 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"58787_CR27","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink, H. J., Perkins, B. A., Fitchett, D. H., Husain, M. & Cherney, D. Z. Sodium-glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation 134, 752\u2013772 (2016).","journal-title":"Circulation"},{"key":"58787_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker, T. A. & Braunwald, E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 422\u2013434 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"58787_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12020-025-04393-7","volume":"90","author":"BT Yoosuf","year":"2025","unstructured":"Yoosuf, B. T. et al. Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomized controlled trials and disproportionality analysis using FAERS. Endocrine 90, 439\u2013452 (2025).","journal-title":"Endocrine"},{"key":"58787_CR30","doi-asserted-by":"publisher","first-page":"k1479","DOI":"10.1136\/bmj.k1479","volume":"361","author":"D Agniel","year":"2018","unstructured":"Agniel, D., Kohane, I. S. & Weber, G. M. Biases in electronic health record data due to processes within the healthcare system: Retrospective observational study. BMJ 361, k1479 (2018).","journal-title":"BMJ"},{"key":"58787_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4093\/dmj.2021.0356","volume":"47","author":"JS Moon","year":"2023","unstructured":"Moon, J. S. et al. Safety and effectiveness of empagliflozin in Korean patients with type 2 diabetes mellitus: Results from a nationwide post-marketing surveillance. Diabetes Metab. J. 47, 82\u201391 (2023).","journal-title":"Diabetes Metab. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58787-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58787-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58787-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:41:45Z","timestamp":1789602105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58787-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58787"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58787-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9402754\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"29010"}}